PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 19, 2026ESMO Open0 citationsOpen Access

107P Health-related quality of life with ivonescimab versus pembrolizumab for PD-L1 positive, non-small cell lung cancer (HARMONi-2): A randomised, double-blind, phase III study in China

View Full Paper
BLB. LiuJYJ. YaoHZH. Zhong

Key Points

  • The aim is to compare health-related quality of life between ivonescimab and pembrolizumab in patients with PD-L1 positive NSCLC.
  • Randomised, double-blind, phase III study design
  • Participants were previously untreated patients with advanced PD-L1 positive NSCLC
  • Comparison of health-related quality of life outcomes between treatments
  • Ivonescimab significantly improved progression-free survival compared to pembrolizumab
  • Safety profile of ivonescimab was manageable
  • Health-related quality of life data were reported from the study

Abstract

In HARMONi-2 study, ivonescimab significantly improved progression free survival (PFS) compared with pembrolizumab in previously untreated patients with advanced PD-L1 positive non-small cell lung cancer (NSCLC), with manageable safety profile. Here we reported health-related quality of life (HRQoL) from HARMONi-2.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/69bb92df496e729e62980976https://doi.org/10.1016/j.esmoop.2026.106414
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.2026 · 2 citations
  2. 2Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.2024 · 14 citations
  3. 3Real-world efficacy and safety of bispecific antibody ivonescimab-based regimens in EGFR-TKI–resistant advanced NSCLC.2026
  4. 4A randomized, active-controlled phase 3 study of ivonescimab + FOLFOX versus bevacizumab + FOLFOX as first-line treatment of metastatic colorectal cancer (mCRC): HARMONi-GI3.2026
  5. 5Ivonescimab Plus Chemo Extends Squamous NSCLC Survival2026